MedPath

Gentamicin Sulfate

(Sterile)

Approved
Approval ID

f6fb1949-a89b-4fe0-afdc-31ca6c02e567

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 29, 2024

Manufacturers
FDA

REMEDYREPACK INC.

DUNS: 829572556

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Gentamicin Sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70518-3785
Application NumberANDA064048
Product Classification
M
Marketing Category
C73584
G
Generic Name
Gentamicin Sulfate
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateMarch 29, 2024
FDA Product Classification

INGREDIENTS (8)

SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORMInactive
Code: 3980JIH2SW
Classification: IACT
SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORMInactive
Code: GR686LBA74
Classification: IACT
GENTAMICIN SULFATEActive
Quantity: 3 mg in 1 mL
Code: 8X7386QRLV
Classification: ACTIM
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 8/1/2023

DRUG: Gentamicin Sulfate

GENERIC: Gentamicin Sulfate

DOSAGE: SOLUTION/ DROPS

ADMINSTRATION: OPHTHALMIC

NDC: 70518-3785-0

PACKAGING: 5 mL in 1 BOTTLE, DROPPER

OUTER PACKAGING: 1 in 1 CARTON

ACTIVE INGREDIENT(S):

  • GENTAMICIN SULFATE 3mg in 1mL

INACTIVE INGREDIENT(S):

  • SODIUM CHLORIDE
  • SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM
  • WATER
  • HYDROCHLORIC ACID
  • SODIUM HYDROXIDE
  • BENZALKONIUM CHLORIDE
  • SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM

Remedy_Label

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 8/1/2023

INDICATIONS AND USAGE

Gentamicin sulfate ophthalmic solution is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms:

Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa,and Serratia marcescens.

CONTRAINDICATIONS SECTION

LOINC: 34070-3Updated: 8/1/2023

CONTRAINDICATIONS

Gentamicin sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 8/1/2023

ADVERSE REACTIONS

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 8/1/2023

CLINICAL PHARMACOLOGY

Microbiology

Gentamicin sulfate is active in vitroagainst many strains of the following microorganisms:

Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa,and Serratia marcescens.

WARNINGS SECTION

LOINC: 34071-1Updated: 8/1/2023

WARNINGS

NOT FOR INJECTION INTO THE EYE

Gentamicin sulfate ophthalmic solution is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 8/1/2023

DOSAGE AND ADMINISTRATION

Instill one or two drops into the affected eye(s) every four hours. In severe infections dosage may be increased to as much as two drops every hour.

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 8/1/2023

Gentamicin sulfate ophthalmic solution USP, 0.3% is supplied sterile in a white LDPE plastic bottle, with a white LLDPE extended controlled drop tip and white polypropylene cap in the following size:

NDC: 70518-3785-00

PACKAGING: 1 in 1 CARTON, 5 mL in 1 BOTTLE, DROPPER TYPE 0

NOT FOR INJECTION INTO THE EYE

FOR OPHTHALMIC USE ONLY

Storage: Store between 2°C to 25°C (36°F to 77°F). Avoid exposure to excessive heat.

KEEP OUT OF REACH OF CHILDREN.

Repackaged and Distributed By:

Remedy Repack, Inc.

625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762

DESCRIPTION SECTION

LOINC: 34089-3Updated: 8/1/2023

DESCRIPTION

Gentamicin sulfate ophthalmic solution, USP is a sterile, aqueous solution buffered to approximately pH 7.0 and formulated for ophthalmic use.

Each mL contains:

**Active:**gentamicin sulfate, USP (equivalent to 3 mg gentamicin).

**Inactives:**dibasic sodium phosphate, sodium chloride, monobasic sodium phosphate, purified water. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (6.5 - 7.5).

**Preservative:**benzalkonium chloride 0.01%.

Gentamicin is an aminoglycoside antibiotic obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, C1a and C2a. All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol.

The structural formula is as follows:

Gentamicin Sulfate (structural formula)

PRECAUTIONS SECTION

LOINC: 42232-9Updated: 8/1/2023

PRECAUTIONS

General

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician. If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Information for Patients

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Repackaged By / Distributed By: RemedyRepack Inc.

625 Kolter Drive, Indiana, PA 15701

(724) 465-8762

Carcinogenesis, Mutagenesis, Impairment of Fertility

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy

Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Gentamicin Sulfate - FDA Drug Approval Details